Evidence map›Paper›PMID 33818906›Full record

ArticleStem cells translational medicine2021

Controlled aggregation enhances immunomodulatory potential of mesenchymal stromal cell aggregates.

Angela W Xie, Nicholas A Zacharias, Bernard Y K Binder, William L Murphy

Open access · goldAbstract read
In one paragraph

Article in Stem cells translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Angela W XieDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0002-7564-4199
Nicholas A ZachariasDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Bernard Y K BinderDepartment of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, Wisconsin, USA.
William L MurphyDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0001-5577-7739
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
BIOTECHNOLOGY TRAINING PROGRAMT32GM008349 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI FOX, BRIAN G · 1989 to 2019
$22.5M
Harnessing human brain and liver microphysiological systems for testing therapeutics for metastatic melanomaU01TR002383 · NCATS · VANDERBILT UNIVERSITY · PI MURPHY, WILLIAM L., TAYLOR, D. LANSING · 2018 to 2022
$7.6M
Biomaterials for local regulation of growth factor signalingR01HL093282 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI MURPHY, WILLIAM L. · 2009 to 2018
$3.3M
A Neurovascular Microphysiological SystemR01NS109427 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI MURPHY, WILLIAM L. · 2019 to 2023
$1.7M
NCATS NIH HHS U01 TR002383NCI NIH HHS P30 CA014520NHLBI NIH HHS R01 HL093282NIGMS NIH HHS T32 GM008349NINDS NIH HHS R01 NS109427
6 · The paper itself

Abstract

Human mesenchymal stromal cells (MSCs) are promising candidates for cell therapy due to their ease of isolation and expansion and their ability to secrete antiapoptotic, pro-angiogenic, and immunomodulatory factors. Three-dimensional (3D) aggregation "self-activates" MSCs to augment their pro-angiogenic and immunomodulatory potential, but the microenvironmental features and culture parameters that promote optimal MSC immunomodulatory function in 3D aggregates are poorly understood. Here, we generated MSC aggregates via three distinct methods and compared them with regard to their (a) aggregate structure and (b) immunomodulatory phenotype under resting conditions and in response to inflammatory stimulus. Methods associated with fast aggregation kinetics formed aggregates with higher cell packing density and reduced extracellular matrix (ECM) synthesis compared to those with slow aggregation kinetics. While all three methods of 3D aggregation enhanced MSC expression of immunomodulatory factors compared to two-dimensional culture, different aggregation methods modulated cells' temporal expression of these factors. A Design of Experiments approach, in which aggregate size and aggregation kinetics were systematically covaried, identified a significant effect of both parameters on MSCs' ability to regulate immune cells. Compared to small aggregates formed with fast kinetics, large aggregates with slow assembly kinetics were more effective at T-cell suppression and macrophage polarization toward anti-inflammatory phenotypes. Thus, culture parameters including aggregation method, kinetics, and aggregate size influence both the structural properties of aggregates and their paracrine immunomodulatory function. These findings underscore the utility of engineering strategies to control properties of 3D MSC aggregates, which may identify new avenues for optimizing the immunomodulatory function of MSC-based cell therapies.

Indexed as

Mesenchymal Stem CellsCell AggregationCell ProliferationCells, CulturedExtracellular MatrixImmunomodulationT-Lymphocytesbone marrow stromal cellscell therapycytokinesmesenchymal stromal cells

Identifiers

PMID33818906
PMCPMC8284773
OpenAlexW3149577751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.